Literature DB >> 30312408

MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.

Leo H Wang1, Seth D Friedman2, Dennis Shaw2,3, Lauren Snider4, Chao-Jen Wong4, Chris B Budech2, Sandra L Poliachik2, Nancy E Gove5, Leann M Lewis6, Amy E Campbell4, Richard J F L Lemmers7, Silvère M Maarel7, Stephen J Tapscott4, Rabi N Tawil6.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a common, dominantly inherited disease caused by the epigenetic de-repression of the DUX4 gene, a transcription factor normally repressed in skeletal muscle. As targeted therapies are now possible in FSHD, a better understanding of the relationship between DUX4 activity, muscle pathology and muscle magnetic resonance imaging (MRI) changes is crucial both to understand disease mechanisms and for the design of future clinical trials. Here, we performed MRIs of the lower extremities in 36 individuals with FSHD, followed by needle muscle biopsies in safely accessible muscles. We examined the correlation between MRI characteristics, muscle pathology and expression of DUX4 target genes. Results show that the presence of elevated MRI short tau inversion recovery signal has substantial predictive value in identifying muscles with active disease as determined by histopathology and DUX4 target gene expression. In addition, DUX4 target gene expression was detected only in FSHD-affected muscles and not in control muscles. These results support the use of MRI to identify FSHD muscles most likely to have active disease and higher levels of DUX4 target gene expression and might be useful in early phase therapeutic trials to demonstrate target engagement in therapies aiming to suppress DUX4 expression.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30312408      PMCID: PMC6337697          DOI: 10.1093/hmg/ddy364

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  36 in total

1.  RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy.

Authors:  Lauren Snider; Amy Asawachaicharn; Ashlee E Tyler; Linda N Geng; Lisa M Petek; Lisa Maves; Daniel G Miller; Richard J L F Lemmers; Sara T Winokur; Rabi Tawil; Silvère M van der Maarel; Galina N Filippova; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2009-04-09       Impact factor: 6.150

2.  Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy.

Authors:  Hermien E Kan; Tom W J Scheenen; Marielle Wohlgemuth; Dennis W J Klomp; Ivonne van Loosbroek-Wagenmans; George W Padberg; Arend Heerschap
Journal:  Neuromuscul Disord       Date:  2009-03-28       Impact factor: 4.296

3.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Authors:  Zizhen Yao; Lauren Snider; Judit Balog; Richard J L F Lemmers; Silvère M Van Der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2014-05-26       Impact factor: 6.150

4.  Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy.

Authors:  Giorgio Tasca; Mauro Monforte; Maddalena Corbi; Giuseppe Granata; Donatella Lucchetti; Alessandro Sgambato; Enzo Ricci
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

5.  Microvascular deposition of complement membrane attack complex in dermatomyositis.

Authors:  J T Kissel; J R Mendell; K W Rammohan
Journal:  N Engl J Med       Date:  1986-02-06       Impact factor: 91.245

6.  Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression.

Authors:  R J Willcocks; I A Arpan; S C Forbes; D J Lott; C R Senesac; E Senesac; J Deol; W T Triplett; C Baligand; M J Daniels; H L Sweeney; G A Walter; K Vandenborne
Journal:  Neuromuscul Disord       Date:  2014-01-11       Impact factor: 4.296

7.  The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein.

Authors:  Valeria Kowaljow; Aline Marcowycz; Eugénie Ansseau; Cecilia B Conde; Sébastien Sauvage; Christel Mattéotti; Cristina Arias; E Daniel Corona; Nicolás G Nuñez; Oberdan Leo; Ruddy Wattiez; Denise Figlewicz; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée; Alberto L Rosa
Journal:  Neuromuscul Disord       Date:  2007-06-27       Impact factor: 4.296

8.  Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype.

Authors:  E Ricci; G Galluzzi; G Deidda; S Cacurri; L Colantoni; B Merico; N Piazzo; S Servidei; E Vigneti; V Pasceri; G Silvestri; M Mirabella; F Mangiola; P Tonali; L Felicetti
Journal:  Ann Neurol       Date:  1999-06       Impact factor: 10.422

Review 9.  Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy.

Authors:  Jedrzej Burakiewicz; Christopher D J Sinclair; Dirk Fischer; Glenn A Walter; Hermien E Kan; Kieren G Hollingsworth
Journal:  J Neurol       Date:  2017-07-01       Impact factor: 4.849

10.  A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD).

Authors:  Lisa M Petek; Amanda M Rickard; Christopher Budech; Sandra L Poliachik; Dennis Shaw; Mark R Ferguson; Rabi Tawil; Seth D Friedman; Daniel G Miller
Journal:  Neuromuscul Disord       Date:  2016-04-22       Impact factor: 4.296

View more
  36 in total

Review 1.  Advancements in magnetic resonance imaging-based biomarkers for muscular dystrophy.

Authors:  Doris G Leung
Journal:  Muscle Nerve       Date:  2019-05-14       Impact factor: 3.217

2.  It's not all about muscle: fibroadipogenic progenitors contribute to facioscapulohumeral muscular dystrophy.

Authors:  Carlo Serra; Kathryn R Wagner
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

3.  SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.

Authors:  Richard J L F Lemmers; Nienke van der Stoep; Patrick J van der Vliet; Steven A Moore; David San Leon Granado; Katherine Johnson; Ana Topf; Volker Straub; Teresinha Evangelista; Tahseen Mozaffar; Virginia Kimonis; Natalie D Shaw; Rita Selvatici; Alessandra Ferlini; Nicol Voermans; Baziel van Engelen; Sabrina Sacconi; Rabi Tawil; Meindert Lamers; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2019-06-26       Impact factor: 6.318

4.  Diagnostic magnetic resonance imaging biomarkers for facioscapulohumeral muscular dystrophy identified by machine learning.

Authors:  Mauro Monforte; Sara Bortolani; Eleonora Torchia; Lara Cristiano; Francesco Laschena; Tommaso Tartaglione; Enzo Ricci; Giorgio Tasca
Journal:  J Neurol       Date:  2021-09-06       Impact factor: 4.849

Review 5.  Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Authors:  Justin Cohen; Alec DeSimone; Monkol Lek; Angela Lek
Journal:  Trends Mol Med       Date:  2020-10-19       Impact factor: 11.951

6.  Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies.

Authors:  Chao-Jen Wong; Leo H Wang; Seth D Friedman; Dennis Shaw; Amy E Campbell; Chris B Budech; Leann M Lewis; Richard J F L Lemmers; Jeffrey M Statland; Silvère M van der Maarel; Rabi N Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

7.  Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.

Authors:  Darko Bosnakovski; Ahmed S Shams; Ce Yuan; Meiricris T da Silva; Elizabeth T Ener; Cory W Baumann; Angus J Lindsay; Mayank Verma; Atsushi Asakura; Dawn A Lowe; Michael Kyba
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

8.  Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Ana Blatnik; Judit Balog; Janez Zidar; Don Henderson; Rianne Goselink; Stephen J Tapscott; Nicol C Voermans; Rabi Tawil; George W A M Padberg; Baziel Gm van Engelen; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2021-01-12       Impact factor: 6.318

Review 9.  Current Therapeutic Approaches in FSHD.

Authors:  Leo H Wang; Rabi Tawil
Journal:  J Neuromuscul Dis       Date:  2021

Review 10.  p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets.

Authors:  Christopher M Brennan; Charles P Emerson; Jane Owens; Nicolas Christoforou
Journal:  JCI Insight       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.